Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CAMN107A2303
NCT00471497
2.
Efficacy and Safety of AMN107 (Nilotinib)Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CAMN107A2201E1
NCT00488150
Last Modified:
4/17/2008
 
First Published:
5/1/2002
3.
Phase II Study of a Non-Myeloablative Conditioning Regimen Comprising Fludarabine and Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Imatinib Mesylate, Dasatinib, or Nilotinib-Responsive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Blast Crisis
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
70 and under
NCI
FHCRC-1581.00
NCI-H02-0087, NCT00036738
First Published:
6/18/2008
4.
Phase I/II Pilot Study of Imatinib Mesylate and Nilotinib After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Approved-not yet active
Any age
NCI, Pharmaceutical / Industry
FHCRC-2223.00
FHCRC-2223.00, FHCRC-IR-6691, NOVARTIS-FHCRC-2223.00, NCT00702403
5.
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
16 and over
Other
2005-0048
NCT00129740
6.
Nilotinib as First-Line Treatment of Ph+ CML in Early Chronic Phase
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
CML0307
NCT00481052
7.
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
CAMN107DIL02
NCT00633295
8.
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Pharmaceutical / Industry
CAMN107AUS09
NCT00644878
9.
Efficacy and Safety of AMN107 in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
20 and over
Pharmaceutical / Industry
CAMN107D1201
NCT00718562
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute